CSL Seqirus inks fifth contract with BARDA, making the partnership now worth $1.14B

Anna Brown

News Reporter

CSL Seqirus has secured a fresh $121.4 million contract with the US Biomedical Advanced Research and Development Authority to manufacture and supply its adjuvant MF59 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CSL Seqirus inks fifth contract with BARDA, making the partnership now worth $1.14B

Anna Brown

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

Judge halts some NIH cuts after 22 states sue

Vertex operations chief Stuart Arbuckle to retire

Merck KGaA confirms interest in acquiring cancer biotech SpringWorks

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

CSL Se­qirus inks fifth con­tract with BAR­DA, mak­ing the part­ner­ship now worth $1.14B

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

CSL Seqirus inks fifth contract with BARDA, making the partnership now worth $1.14B